免疫抑制是否增加腹横肌松解术后围术期伤口并发症
本研究回顾性分析321例择期开放或机器人双侧腹横肌松解联合永久合成补片患者,按围术期免疫抑制分层。63例(19.6%)存在慢性免疫抑制,最常见指征为实体器官移植(43例)。按免疫抑制分层未发现任何伤口事件差异,进一步按术式分层亦无差异,提示免疫抑制可能并未显著增加腹横肌松解术后围术期伤口并发症风险。
要点
- 腹横肌松解术后慢性免疫抑制者与未免疫抑制者伤口事件无差异
- 按开放或机器人术式进一步分层后仍未发现伤口事件差异
- 免疫抑制不应单独视为腹横肌松解术后伤口并发症的显著危险因素
核心结论
- 慢性免疫抑制可能并未显著增加腹横肌松解术后围术期伤口并发症风险,与既往预期不同。
研究设计与样本
- 回顾性研究,纳入321例择期开放或机器人双侧腹横肌松解联合永久合成补片患者,按围术期免疫抑制分层,并二次按术式与免疫抑制分层。
主要发现
- 63例(19.6%)患者存在慢性免疫抑制,最常见指征为实体器官移植(43例)。
- 按免疫抑制分层,缺损大小(P = .97)、BMI≥30(P = .32)、糖尿病(P = .09)、手术部位感染史(P = .53)、手术方式(P = .53)与吸烟史(P = .33)均匹配。
- 按免疫抑制分层未发现任何伤口事件差异,进一步按术式分层亦无差异。
临床怎么用
- 对于接受腹横肌松解术的慢性免疫抑制患者,不应仅凭免疫抑制状态预判其围术期伤口并发症风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transversus abdominis release is an effective procedure for complex ventral hernias. As wound complications contribute to hernia recurrences, mitigating risk factors is vitally important for hernia surgeons. Although immunosuppression can impair wound healing, it has inconsistently predicted wound occurrences, and its effect on wound morbidity after a transversus abdominis release is unknown. METHODS: Patients undergoing either an elective open or robotic bilateral transversus abdominis release with permanent synthetic mesh were retrospectively stratified by perioperative immunosuppression and secondarily by procedure type (open versus robotic) and immunosuppression. RESULTS: A total of 321 patients were included for analysis. Overall, 63 (19.6%) patients were on chronic immunosuppression, with history of solid-organ transplant being the most common indication (43 patients). Patients stratified by perioperative immunosuppression were well-matched with similar defect size (P = .97), body mass index ≥30 (P = .32), diabetes (P = .09), history of surgical site infection (P = .53), surgical approach (P = .53), and tobacco use history (P = .33). No differences between cohorts were elicited for any wound event when stratified by immunosuppression use. Similarly, no differences were elicited when cohorts were further stratified also by procedure type. CONCLUSION: Chronic immunosuppression is often viewed as a notable risk factor for wound occurrences after surgery. However, our data suggest immunosuppression may not significantly increase the risk of perioperative wound morbidity follow transversus abdominis release as previously predicted.
引用
- Kushner BS, Han B, Holden SE, et al. Does immunosuppression increase perioperative wound morbidity in patients undergoing transversus abdominis release? Surgery. 2021. PMID: 34474933. doi:10.1016/j.surg.2021.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。